Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Olaratumab (Primary) ; Dexrazoxane; Doxorubicin
- Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Myxoid liposarcoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Registrational; Therapeutic Use
- Acronyms ANNOUNCE
- Sponsors Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan
- 17 Jan 2024 Planned End Date changed from 31 Dec 2024 to 31 Jul 2024.
- 24 Oct 2023 Results (n=632) assessing the effect of doxorubicin dose on survival using individual data from the phase II and phase III studies exploring olaratumab in advanced soft tissue sarcoma, presented at the 48th European Society for Medical Oncology Congress.
- 14 Sep 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.